Lactate-mediated activation of GPR81 regulates BCR/Abl protein expression in chronic myeloid leukemia cells selected under low oxygen tension.

IF 5.2 2区 医学 Q1 ONCOLOGY
Giulio Menegazzi, Dayana Desideri, Alessio Biagioni, Elisabetta Rovida, Persio Dello Sbarba, Silvia Peppicelli
{"title":"Lactate-mediated activation of GPR81 regulates BCR/Abl protein expression in chronic myeloid leukemia cells selected under low oxygen tension.","authors":"Giulio Menegazzi, Dayana Desideri, Alessio Biagioni, Elisabetta Rovida, Persio Dello Sbarba, Silvia Peppicelli","doi":"10.1002/path.6492","DOIUrl":null,"url":null,"abstract":"<p><p>Chronic myeloid leukemia (CML) is a stem cell-driven neoplasia characterized by the expression of the constitutively active tyrosine kinase (TK) BCR/Abl. Under low oxygen, a condition that characterizes stem cell niches (SCNs) in vivo, the oncogenic BCR/Abl<sub>protein</sub> is suppressed. Consequently, leukemia stem cells (LSCs) residing within SCNs show resistance to TK inhibitors (TKIs), the first-line therapy for CML, due to the lack of their molecular target. It is therefore important to deepen understanding of the mechanisms driving BCR/Abl<sub>protein</sub> suppression to design new strategies able to repress TKI-resistant LSCs. Our previous studies showed that BCR/Abl<sub>protein</sub> suppression occurred when glucose approaches completed exhaustion in culture medium. As lactate is the main byproduct of glucose catabolism in low oxygen, in this study we addressed the role of lactate in regulating BCR/Abl<sub>protein</sub> expression. We found that treatment of CML cells with 2-DG, which blocks glycolysis and thereby lactate production, or monocarboxylate transporter (MCT) inhibitors, which reduce lactate excretion, enhanced BCR/Abl<sub>protein</sub> expression and promoted maintenance of a BCR/Abl-dependent/TKI-sensitive stem cell phenotype. The effects of MCT inhibition were abolished when exogenous lactate was added to culture medium, resulting in the suppression of BCR/Abl<sub>protein</sub> expression. Treatment with 3-hydroxy-butyrate acid, an antagonist of the GPR81 plasma membrane 'lactate' receptor, prevented lactate-driven BCR/Abl<sub>protein</sub> suppression, while the selective GPR81 agonist 3-chloro-5-hydroxy-BA counteracted the maintenance of BCR/Abl<sub>protein</sub> induced by MCT inhibition. Our results indicate that GPR81 engagement by extracellular lactate determines BCR/Abl<sub>protein</sub> suppression in low oxygen environments. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.</p>","PeriodicalId":232,"journal":{"name":"The Journal of Pathology","volume":" ","pages":""},"PeriodicalIF":5.2000,"publicationDate":"2025-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of Pathology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/path.6492","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Chronic myeloid leukemia (CML) is a stem cell-driven neoplasia characterized by the expression of the constitutively active tyrosine kinase (TK) BCR/Abl. Under low oxygen, a condition that characterizes stem cell niches (SCNs) in vivo, the oncogenic BCR/Ablprotein is suppressed. Consequently, leukemia stem cells (LSCs) residing within SCNs show resistance to TK inhibitors (TKIs), the first-line therapy for CML, due to the lack of their molecular target. It is therefore important to deepen understanding of the mechanisms driving BCR/Ablprotein suppression to design new strategies able to repress TKI-resistant LSCs. Our previous studies showed that BCR/Ablprotein suppression occurred when glucose approaches completed exhaustion in culture medium. As lactate is the main byproduct of glucose catabolism in low oxygen, in this study we addressed the role of lactate in regulating BCR/Ablprotein expression. We found that treatment of CML cells with 2-DG, which blocks glycolysis and thereby lactate production, or monocarboxylate transporter (MCT) inhibitors, which reduce lactate excretion, enhanced BCR/Ablprotein expression and promoted maintenance of a BCR/Abl-dependent/TKI-sensitive stem cell phenotype. The effects of MCT inhibition were abolished when exogenous lactate was added to culture medium, resulting in the suppression of BCR/Ablprotein expression. Treatment with 3-hydroxy-butyrate acid, an antagonist of the GPR81 plasma membrane 'lactate' receptor, prevented lactate-driven BCR/Ablprotein suppression, while the selective GPR81 agonist 3-chloro-5-hydroxy-BA counteracted the maintenance of BCR/Ablprotein induced by MCT inhibition. Our results indicate that GPR81 engagement by extracellular lactate determines BCR/Ablprotein suppression in low oxygen environments. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

乳酸介导的GPR81激活调节低氧应激下慢性髓系白血病细胞BCR/Abl蛋白的表达。
慢性髓性白血病(CML)是一种干细胞驱动的肿瘤,其特征是组成型活性酪氨酸激酶(TK) BCR/Abl的表达。在低氧条件下,这是体内干细胞龛(SCNs)的特征,致癌的BCR/ abl蛋白被抑制。因此,由于缺乏分子靶点,居住在scn内的白血病干细胞(LSCs)对TK抑制剂(TKIs) (CML的一线治疗药物)表现出耐药性。因此,深化对BCR/Ablprotein抑制机制的理解对于设计能够抑制tki抗性LSCs的新策略非常重要。我们之前的研究表明,当葡萄糖在培养基中接近完全耗尽时,BCR/Ablprotein会发生抑制。由于乳酸是低氧条件下葡萄糖分解代谢的主要副产物,在本研究中,我们研究了乳酸在调节BCR/Ablprotein表达中的作用。我们发现用2-DG或MCT抑制剂治疗CML细胞,前者可阻断糖酵解从而产生乳酸,后者可减少乳酸排泄,增强BCR/ abl蛋白表达,促进BCR/ abl依赖性/ tki敏感干细胞表型的维持。在培养基中加入外源乳酸可消除MCT抑制作用,抑制BCR/Ablprotein的表达。3-羟基丁酸(一种GPR81质膜“乳酸”受体拮抗剂)可阻止乳酸驱动的BCR/Ablprotein抑制,而选择性GPR81激动剂3-氯-5-羟基ba可抵消MCT抑制诱导的BCR/Ablprotein维持。我们的研究结果表明,低氧环境下,细胞外乳酸与GPR81的结合决定了BCR/Ablprotein的抑制。©2025作者。《病理学杂志》由John Wiley & Sons Ltd代表大不列颠和爱尔兰病理学会出版。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
The Journal of Pathology
The Journal of Pathology 医学-病理学
CiteScore
14.10
自引率
1.40%
发文量
144
审稿时长
3-8 weeks
期刊介绍: The Journal of Pathology aims to serve as a translational bridge between basic biomedical science and clinical medicine with particular emphasis on, but not restricted to, tissue based studies. The main interests of the Journal lie in publishing studies that further our understanding the pathophysiological and pathogenetic mechanisms of human disease. The Journal of Pathology welcomes investigative studies on human tissues, in vitro and in vivo experimental studies, and investigations based on animal models with a clear relevance to human disease, including transgenic systems. As well as original research papers, the Journal seeks to provide rapid publication in a variety of other formats, including editorials, review articles, commentaries and perspectives and other features, both contributed and solicited.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信